Medtronic restructures, combining all CV units into one

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Medtronic today announced plans to combine its cardiac rhythm disease management (CRDM), cardiovascular and Physio-Control businesses into one group; and combine its spinal and biologics, neuromodulation, diabetes and surgical technologies businesses. Also, its newly formed cadiovascular division is looking for a new leader.

Effective immediately, the Minneapolis-based company will consolidate its businesses into two operating groups.

Chairman and CEO Bill Hawkins said that the new structure would allow the company to operate in a more unified manner "to capitalize on existing synergies."

The new combined CRDM, cardiovascular and Physio-Control Group is currently conducting an external search for a new executive vice president (VP) and group president. Reporting to this leader will be Pat Mackin, senior VP and president of CRDM; Scott Ward, senior VP and president of cardiovascular; and Brian Webster, president of the Redmond, Wash.-based Physio-Control.

For the new spinal and biologics, neuromodulation, diabetes and surgical technologies group, Chris O’Connell has been promoted to the new position of executive VP and group president for this newly created group. O’Connell was formerly president of the company’s diabetes business. Reporting to O’Connell will be Bob Blankemeyer, senior VP and president of surgical technologies; Steve La Neve, senior VP and president of spinal and biologics; Katie Szyman, who has been named as senior VP and president of diabetes, and formerly served as senior VP of strategy and innovation; and Tom Tefft, who has been named senior VP and president of neuromodulation, and formerly served as VP and corporate controller.

Medtronic also said that Jean-Luc Butel has been promoted to the new position of executive VP and group president of international operations, of which he was formerly senior VP and president.

Finally, Rick Kuntz, MD, has been named senior VP and chief scientific, clinical and regulatory officer. Kuntz was formerly senior VP and president of neuromodulation.